Onychomycosis to Fungal Superinfection: Prevention Strategies and Considerations

October 2015 | Volume 14 | Issue 10 | Supplement Individual Articles | 32 | Copyright © October 2015


Joshua A. Zeichner MD

Department of Dermatology, Mount Sinai Hospital, New York, NY

table 3
cured, it can take up to a year for an abnormal nail to grow out. In the event that the nail matrix itself becomes damaged, then a new nail that is produced will appear abnormal, even if the previous fungal infection has been cleared.

CONCLUSION

Onychomycosis is a common nail disease that carries a significant health burden. While many practitioners may overlook onychomycosis, it warrants treatment. Onychomycosis is commonly associated with concurrent tinea pedis, which should be evaluated for and treated along with the nails to prevent spread and reinfection. Failure to treat onychomycosis can put patients at risk for nail pain, permanent deformity, potential superinfection, and quality of life impairment.

DISCLOSURES

Joshua A. Zeichner MD is an advisory board member, consultant, investigator, and speaker for Valeant Pharmaceuticals; and an advisory board member for Anacor, Exeltis, and PharmaDerm.

REFERENCES

  1. Scher RK, Rich P, Pariser D, Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;32(2 suppl 1):s2-s4
  2. Drake L, Dinehart SR, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Onychomycosis. J Am Acad Dermatol. 1996;34(1):16-21.
  3. Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol. 2010;28(2):197-201.
  4. The National Disease and Therapeutic Index™ (NDTI) Data, September 2013.
  5. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. J Clin Pharm Ther. 2010;35(5):497-519.
  6. Rich P, Elewski B, Scher RK, Pariser D. Semin Cutan Med Surg. 2013;32(2 suppl 1):s5-s8.
  7. Pariser D. The rationale for renewed attention to onychomycosis. Semin Cutan Med Surg. 2013;32(2 suppl 1):s1.
  8. Salgo PL, Daniel CR, Gupta AK, et al. Onychomycosis disease management. Medical Crossfire: Debates, peer exchange and insights in medicine. 2003.
  9. Gupta AK, Lynch LE. Onychomycosis: a review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis. 2004;74(suppl 1):s10-s15.
  10. Lipner SR, Scher RK. Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol. 2015;14(5):492-494.
  11. Daniel CR 3rd, Jellinek NJ. The pedal fungus reservoir. Arch Dermatol. 2006;142(10):1344-1346.
  12. Blake N. Onychomycosis, routine callus care, diabetic foot examination in the outpatient setting and update on prescription foot orthoses. Curr Opin Orthop. 2005;16:50-53.
  13. Sigurgeirsson B, Steingrímsson O. Risk factors associated with onychomycosis. J Eur Acad Derm Venereol. 2004;18(1):48-51.
  14. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. J Clin Pharm Ther. 2010;35(5):497-519.
  15. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3)415-429.
  16. Rich P. Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early. J Drugs Dermatol. 2015;14(1):58-62.
  17. Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychmycosis in Algeria. Mycoses. 2006;49(3):190-196.
  18. Tan JS, Joseph WS. Common fungal infections of the feet in patients with diabetes mellitus. Drugs Aging. 2004;21(2):101-112.
  19. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497-519.
  20. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf. 2000;22(1):33-52.
  21. Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc. 1997;87(12):546-550.
  22. Elewski BE. Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol. 2000;1(1):19-26.
  23. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol. 1999;41(2 pt 1):189-196.
  24. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol. 1997;36(10):754-756.
  25. Elewski B, Pariser D, Rich P, Scher RK. Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg. 2013;32(2 suppl 1):s9-s12.

AUTHOR CORRESPONDENCE

Joshua A. Zeichner MD……..................... joshua.zeichner@mountsinai.org
Close Menu